Leleu, X. Beksac, M. Chou, T. Dimopoulos, M. Yoon, S.-S. Prince, H.M. Pour, L. Shelekhova, T. Chari, A. Khurana, M. Zhang, J. Obreja, M. Qi, M. Oriol, A. Siegel, D., Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies, Clinical Lymphoma Myeloma and Leukemia, (62), 358-367, 2021, Taylor and Francis Ltd.,